If you personally know anyone that has dealt with cancer in this lifetime, you understand that the disease drains one completely, and that beating it needs a lot of care with the best quality medical solutions. Well, one person that has a dream to deal with this menace in completeness is Clay Siegall and his company, Seattle Genetics. The recent success that has been enjoyed by the clinical stage company is enough evidence that he might just single handedly make a breakthrough in the field.
Seattle Genetics was started in 1997. When he was starting out, Clay did not have many resources. The dream to treat most if not all of the cancer types affecting modern humanity was the main goal for him. Well, currently, the company already has a drug that has been approved by the FDA for the treatment of several types of lymphomas, and there are about 12 other drugs that are in the testing stage. The company is doing so well that they are already listed on NASDAQ as SGEN. The shares trade fairly well and have been in fact improving over the past couple of years.
In a bid to expand the company even further, Clay has embarked on a recruitment drive. They are hoping to get at least 100 more employees to assist them with their new drugs testing processes. They have reported that one of the drugs they are testing is doing really well and it is hoped that it will be approved within the year. The drug is also being tested for use to treat different types of lymphomas.
The company’s sales have also been really good. In the previous financial year, they made sales of more than a quarter million dollars from their distributors all over the world. In Canada, they are assisted by Takeda Pharmaceuticals in distributing the drug. The drug has also been approved for sale in 60 other countries besides the US and Canada. Clay Siegall says that he has reached this level of success because he never gave up on his vision, and that he hopes that he will indeed be part of the team that will cure cancer once and for all.